Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase by Bakshi, Rahul P. et al.
11040-9238/01/$.50
© 2001 by CRC Press LLC
Critical Reviews in Biochemistry and Molecular Biology, 36(1):1–37 (2001)
Functional and Regulatory Characteristics
of Eukaryotic Type II DNA Topoisomerase
Rahul P. Bakshi, Sanjeev Galande, and K. Muniyappa*
Department of Biochemistry, Indian Institute of Science, Bangalore 560 012
ABSTRACT: DNA topoisomerases are ubiquitous nuclear enzymes that govern the topo-
logical interconversions of DNA by transiently breaking/rejoining the phosphodiester back-
bone of one (type I) or both (type II) strands of the double helix. Consistent with these
functions, topoisomerases play key roles in many aspects of DNA metabolism. Type II
DNA topoisomerase (topo II) is vital for various nuclear processes, including DNA repli-
cation, chromosome segregation, and maintenance of chromosome structure. Topo II
expression is regulated at multiple stages, including transcriptional, posttranscriptional, and
posttranslational levels, by a multitude of signaling factors. Topo II is also the cellular target
for a variety of clinically relevant anti-tumor drugs. Despite significant progress in our
understanding of the role of topo II in diverse nuclear processes, several important aspects
of topo II function, expression, and regulation are poorly understood. We have focused this
review specifically on eukaryotic DNA topoisomerase II, with an emphasis on functional
and regulatory characteristics.
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I. INTRODUCTION
Over 3 decades ago, J. Vinograd and
his colleagues discovered that polyoma
virus chromosome was a circular, double-
stranded, supercoiled DNA (Weil and
Vinograd, 1963; Vinograd et al., 1965).
This observation implied that the enzy-
matic machinery involved in duplication
of DNA faces a formidable problem in
ensuring faithful replication of genetic
material. The biological solutions to such
topological problems were revealed by the
discovery of DNA topoisomerase I, origi-
nally denoted as omega protein (Wang,
1971), followed by DNA gyrase (Gellert
et al., 1976) from Escherichia coli. It is
now established that Escherichia coli en-
codes four distinct topoisomerases. These
include topoisomerase I (topA) (Wang,
1971), topoisomerase II (gyrA and gyrB)
(Gellert et al., 1976), topoisomerase III
(topB) (DiGate and Marians, 1988), and
topoisomerase IV (parC and parE) (Kato
et al., 1990, 1992). These enzymes per-
form various nonoverlapping functions in
vivo (reviewed in Roca, 1995). Addition-
ally, a “reverse gyrase”, capable of intro-
ducing positive supercoils into DNA, in
Cr
iti
ca
l R
ev
ie
w
s i
n 
Bi
oc
he
m
ist
ry
 a
nd
 M
ol
ec
ul
ar
 B
io
lo
gy
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
12
2.
17
9.
87
.1
18
 o
n 
03
/0
2/
11
Fo
r p
er
so
na
l u
se
 o
nl
y.
2an ATP-dependent manner, has been
characterized from hyperthermophiles
(Kikuchi and Asai, 1984; Kozyavkin et
al., 1994).
Before discussing functional and regula-
tory characteristics of topo II, it is useful to
define certain concepts of DNA topology. The
superhelical density of a covalently closed
circular duplex molecule can be defined using
three parameters: the linking number (Lk), the
twist (Tw), and the writhe (Wr). The linking
number (Lk) represents the number of times
one strand of the duplex crosses over the other
when viewed on a planar surface. The linking
number can be partitioned into twist and writhe
(Lk = Tw + Wr). The twist (Tw) represents
the local twist of the helix and writhe (Wr) is
the measure of the local contortion of the helix
axis in space. Lk is necessarily integral, while
Tw and Wr are not. For completely relaxed
DNA (Lk = Lk0), Lk0 = Tw0 + Wr0, where Wr0
may have a finite value based on the environ-
ment, DNA isolated from most natural sources
is underwound (i.e., Lk < Lk0). To maximize
base pairing, such a molecule adopts a nega-
tive writhe and is considered negatively su-
percoiled. Similarly, a molecule with a posi-
tive writhe (i.e., overwound) is considered
positively supercoiled. Negative supercoiling
is physiologically important as underwound
DNA facilitates cellular processes that require
strand separation, such as transcription, re-
combination, and replication. It must be noted
that the linking number of a DNA molecule is
a topological invariant. A change in linking
number involves the breaking of one or both
strands of the duplex. Cellular processes re-
quiring topological changes therefore are de-
pendent on the components that catalyze such
modifications viz. DNA topoisomerases (re-
viewed in Wang, 1985, 1987; Maxwell and
Gellert, 1986).
 A fundamental feature of all topo-
isomerases is their innate ability to transiently
cleave and reseal the phosphodiester back-
bone of DNA via a transesterification reac-
tion. This cleavage gives rise to a covalent
enzyme-DNA intermediate with the tyrosine
hydroxyl group of the topo-isomerase linked
to the 5' or 3' phosphate. The ability of these
enzymes to generate either a single- or a
double-strand break in the DNA has led to
their classification as type I or type II en-
zymes. Strand passage by type I enzymes
leads to changes in linking number in steps
of 1 and is independent of the binding or
hydrolysis of ATP (except reverse gyrase).
Strand passage by type II enzymes is coupled
to ATP hydrolysis and leads to changes in
linking number in steps of 2. The ability to
create a double-strand break confers, on type
II enzymes, the capacity to catalyze a variety
of topological interconversions, including
relaxation of negatively supercoiled DNA
and the decatenation of interlinked duplex
molecules. The latter reaction is specific to
topoisomerase II and underlies its role in
other cellular processes, such as chromosome
segregation and sister chromatid separation.
II. TYPE II DNA
TOPOISOMERASES IN
EUKARYOTES
 The discovery of topoisomerase I (Wang,
1971) was followed by the identification of a
similar activity in cell-free extracts of cul-
tured mouse cells (Champoux and Dulbecco,
1972). Utilizing the assays developed for the
identification and isolation of prokaryotic
topoisomerases, a number of type I and type
II enzymes have been identified, their genes
cloned, and characterized from a variety of
eukaryotic organisms (reviewed in Wang,
1996; Watt and Hickson, 1994). One signifi-
cant feature that has emerged from these stud-
ies is that, unlike E. coli DNA gyrase, none
of the known eukaryotic type II enzymes are
endowed with supercoiling activity. The lit-
erature associated with the studies on eu-
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3karyotic topoisomerases is exhaustive and
has been reviewed extensively (Watt and
Hickson, 1994; Wang, 1996). This review
emphasizes the progress made in understand-
ing cellular regulation and the roles of eu-
karyotic topoisomerase II in multiple aspects
of DNA metabolism.
A. Topoisomerase II from Yeasts
Because of the simplicity and extensive
genetic understanding of yeasts, much of our
current knowledge of the mechanistic aspects
of eukaryotic type II DNA topoisomerase has
been derived from studies on yeast topo II.
Topo II has been purified from Saccharomy-
ces cerevisiae and Schizosaccharomyces
pombe. The enzyme is a single polypeptide of
150 kDa (Goto et al., 1984) and 165 kDa
(Shiozaki and Yanagida, 1991), respectively.
Gel filtration and sedimentation analyses re-
vealed that topo II exists as a homodimer in
solution (Goto et al., 1984). Isolation and se-
quence characterization of TOP2 genes from
both these organisms (Goto and Wang, 1984;
Uemura et al., 1986) revealed extensive struc-
tural homology between yeast topo II and
E. coli DNA gyrase. The N-terminal and C-
terminal domains of yeast topo II are exten-
sively homologous to the GyrB and GyrA
subunits of E. coli gyrase, respectively (Giaever
et al., 1986; Lynn et al., 1986; Uemura et al.,
1986). These results suggest that eukaryotic
topo II is likely to have evolved from the
fusion of gyrA and gyrB genes.
B. Topoisomerase II from
Drosophila
Topo II from Drosophila melanogaster
has been extensively utilized for the elucida-
tion of the mechanistic aspects of the reac-
tion promoted by eukaryotic topo II. The
enzyme was purified from embryo extracts
and was shown to reversibly catenate DNA
in an ATP-dependent manner (Hsieh and
Brutlag, 1980; Shelton et al., 1983). Droso-
phila topo II is a 166-kDa polypeptide and
exists as a dimer in solution (Shelton et al.,
1983). TOP2 gene from Drosophila has been
isolated and characterized. It is a single copy
gene located near the centromere of chromo-
some 2 at position 37D (Nolan et al., 1986).
A comparison of nucleotide sequences indi-
cates significant homology among the TOP2
of Drosophila, S. cerevisiae, and S. pombe,
and DNA gyrase of Bacillus subtilis (Nolan
et al., 1986; Wyckoff et al., 1989).
C. Topoisomerase II in
Vertebrates
Studies on topoisomerase II from ver-
tebrates, including human (Drake et al.,
1987, 1989), mouse (Adachi et al., 1992),
rat (Tsutsui et al., 1993; Park et al., 1993),
and hamster (Dereuddre et al., 1995) have
revealed the existence of two isoforms of
topo II: topo IIα and topo IIβ. They are
highly similar but genetically distinct and
display different expression patterns. In
vivo studies have revealed that topo IIα is
expressed in developing tissues such as
thymus and testis, while topo IIβ is ex-
pressed in somatic tissues (Holden et al.,
1990; Capranico et al., 1992; Juenke and
Holden, 1993; Galande and Muniyappa,
1996). The genes for human topo IIα and
topo IIβ have been isolated and character-
ized extensively (Tsai-Pflugfelder et al.,
1988; Tan et al., 1992; Lang et al., 1998);
these encode polypeptides of 170 and 180
kDa, respectively. Topo IIα gene has been
mapped to chromosome 17q21-22 (Tsai-
Pflugfelder et al., 1988), while topo IIβ
gene resides on chromosome 3p24 (Tan et
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4al., 1992). Interestingly, human cells pro-
duce a variant form of topo IIβ that is five
amino acid residues longer and is gener-
ated by alternative splicing (Davies et al.,
1993). Human topo IIα and topo IIβ have
been purified and biochemically character-
ized (Drake et al., 1989; Chung et al., 1989;
Austin et al., 1995). They differ in various
enzymatic parameters in vitro, including
reaction processivity, sensitivity to ionic
strength, thermal stability, and drug sensi-
tivity (Drake et al., 1989). These isoforms
normally exist as homodimers. However, a
small proportion of αβ heterodimers has
been detected in cultured cells (Biersack et
al., 1996). These are biochemically dis-
tinct from homodimers (Gromova et al.,
1998), but their physiological significance
remains obscure. There is evidence to sug-
gest that human topo IIα and topo IIβ might
perform nonoverlapping functions in vivo
(Meyer et al., 1997; Grue et al., 1998). In
this regard, we note that homozygous topo
IIβ mutant mice failed to connect motor
axons to skeletal muscles, and sensory
axons failed to enter the spinal cord. These
defects led to breathing impairment and
neonatal death (Yang et al., 2000).
D. Topoisomerase II from
Parasites
 Parasitic diseases are among the lead-
ing causes of morbidity and mortality
worldwide. The importance of topo II is
underscored by the fact that topo II is the
cellular target for therapeutic intervention
and control of these diseases (Wang,
1996). In recent years, there has been an
increasing interest in topo II from para-
sites with the aim of developing potent
antiparasitic chemotherapies (Nenortas et
al., 1998). Biochemical studies led to the
identification and characterization of topo
II in trypanosomes (Douc-Rasy et al.,
1986), Leishmania donovani (Chakraborty
and Majumder, 1987, 1991), Crithidia
fasciculata (Shlomai et al., 1984; Melendy
and Ray, 1989), Plasmodium species (Riou
et al., 1986; Chavalitshewinkoon et al.,
1994), and Giardia lamblia (Bell et al.,
1993). Subsequently, genes that encode
topo II have been isolated and character-
ized from Trypanosoma brucei (Strauss
and Wang, 1990), C. fasciculata (Pasion
et al., 1992), and Plasmodium falciparum
(Cheesman et al., 1994). The molecular
masses of topo II from these organisms
are in the range of 137 to 160 kDa. Se-
quence comparisons suggest that the para-
site topo II is related to human enzyme
and contains conserved DNA binding,
dimerization, and ATPase domains
(Nenortas et al., 1998). The genome se-
quences of all the parasites examined so
far indicate the presence of a single copy
of topo II gene. However, data from
immunolocalization (Melendy et al., 1988)
and inhibitor studies (Shapiro and
Englund, 1990) indicate that topo II in the
nucleus and mitochondria may be bio-
chemically distinct.
E. Topoisomerase II in Plants
 Data obtained from plants have helped
establish the universality of topo II in eukary-
otes. Two groups have reported the isolation
and characterization of topo II homologues from
Arabidopsis thaliana (Xie and Lam; 1994a;
1994b) and pea (Reddy et al., 1999). Others
have identified and characterized topo II activ-
ity in nuclear extracts of Zea mays (Carballo et
al., 1991). Computer analysis of structural and
evolutionary relationships show that topo II
from Arabidopsis and pea display significant
homology with human, Drosophila and yeast
topo II (Xie and Lam; 1994a; 1994b; Reddy et
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5al., 1999). There has been an increasing interest
in elucidating the role of topo II in plant growth
and development. In this regard, the connection
between topo II expression and growth regula-
tory signals has been strengthened by the dem-
onstration that topo II expression in actively
dividing tissues is modulated by light and phy-
tohormones (Carballo et al., 1991; Xie and
Lam,1994b; Reddy et al., 1999).
III. MECHANISTIC ASPECTS OF
EUKARYOTIC TYPE II DNA
TOPOISOMERASE
 In recent years, the molecular mechanism
of the topo II promoted reaction has been the
focus of intense investigation. While the gen-
eral mechanistic aspects of the catalytic cycle
have been elucidated, the molecular details are
still obscure. The canonical catalytic mecha-
nism employed by this dyadic enzyme involves
the following steps: Topo II binds the first
DNA segment (referred to as the G segment),
inflicts a double-strand break, and remains co-
valently linked to the DNA. ATP binding to the
N-terminal domain results in a structural change
in topo II, which is believed to facilitate captur-
ing of another segment (the T segment). This
structural change also leads to the enlargement
of the gate in the G segment to permit strand
passage. Concomitantly, the T segment is guided
through the protein-DNA gate, resulting in a
change in the topology of the substrate. ATP
hydrolysis results in turnover of the enzyme,
thereby initiating the cycling of the molecular
machine.
A. Substrate Recognition and
Binding
 A variety of assays have been used to
examine the binding of topo II to DNA.
These include glass-fiber and nitrocellulose
filter-binding (Sander et al., 1987; Roca and
Wang, 1992), electrophoretic mobility shift
(Osheroff, 1986; Bechert et al., 1994), nu-
clease protection (Spitzner and Muller, 1988;
Lee et al., 1989), and electron microscopy
(Zecheidrich and Osheroff, 1990; Howard
et al., 1991). These methods, along with
cleavage studies (Udvardy and Schedl,
1991), indicate that the structure, rather than
the sequence of DNA, is crucial for topo II
binding. In addition, nuclease protection
assays have revealed that topo II protects 20
to 30 bp around its recognition site (Lee et
al., 1989; Thomsen et al., 1990).
 A number of observations suggest that
eukaryotic topo II binds a variety of DNA
substrates, including scaffold-associated re-
gions (Adachi et al., 1989; Käs and Laemmli,
1992), Z-DNA (Glikin et al., 1991; Arndt-
Jovin et al., 1993; Choi et al., 1995), bent
DNA (Howard et al., 1991), hairpins
(Froelich-Ammon et al., 1994), tetraplexes
(Chung et al., 1992), telomeric DNA (Yoon
et al., 1998) and intra- or intermolecular
crossovers (Zecheidrich and Osheroff, 1990;
Roca et al., 1993). Although binding to cross-
overs is consistent with its inherent prop-
erty of strand passage, quantitative analysis
has revealed that binding to crossovers is
not essential for gating (Roca et al., 1993).
It must be noted that despite extensive in-
vestigations of this particular aspect, the
molecular mechanism of DNA substrate
recognition by topo II is obscure.
B. DNA Cleavage and Religation
After binding to its substrate, in the pres-
ence of Mg2+, topo II inflicts a 4 bp-stag-
gered break in the DNA, forming a 5'-
phosphotyrosine enzyme-DNA intermediate
with one strand covalently linked to a mono-
mer of topo II (Liu et al., 1983; Sander and
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6Hsieh, 1983). The reaction is isoenergetic,
does not require a nucleotide cofactor, and
exists in a cleavage-religation equilibrium.
The latter step is an important focal point
for various clinically important anti-tumor
drugs (see below), which act by uncoupling
the cleavage/religation reaction (Tewey et
al., 1984; Chen et al., 1984). By stabilizing
the “cleavable” intermediate, these drugs
have facilitated the analysis of various as-
pects of the reaction, including sequence
preference, kinetics, and the nature of vari-
ous intermediates (Zecheidrich et al., 1989).
These studies have revealed a broad corre-
lation between cleavage sites in vitro and in
vivo (Udvardy et al., 1986; Sander et al.,
1987; Udvardy and Schedl, 1993); how-
ever, chromatin organization might regulate
site accessibility in vivo (Udvardy et al.,
1986; Capranico et al., 1990; Galande and
Muniyappa, 1997). Attempts at generating
a ‘consensus’ cleavage site led to the find-
ing that eukaryotic topo II from a wide va-
riety of sources preferentially cleaves at
purine•pyrimidine (R•Y) repeats (Spitzner
et al., 1990). However, the stringency of
recognition is moderate, and there exist spe-
cies-specific cleavage sites that bear low
sequence homology to the consensus site
(Sander and Hsieh, 1985; Spitzner and
Muller, 1988; Burden and Osheroff, 1999).
It was also demonstrated that binding of a
second segment of DNA to the dimer stimu-
lates the cleavage reaction (Corbett et al.,
1992a).
C. ATP Binding and Hydrolysis
 The role of ATP hydrolysis in the cata-
lytic cycle has been the subject of exten-
sive investigation. Topo II binds ATP co-
operatively and this binding triggers an
interdomain conformational change in the
dimer (Lindsley and Wang, 1991; Lindsley
and Wang, 1993a). The conformational
transition is believed to play a role in trap-
ping the T segment and enlarging the G
segment gate to allow passage of a second
segment (Berger and Wang, 1996; Wigley,
1996). ATPase activity of Drosophila topo
II (Osheroff et al., 1983), yeast topo II
(Lindsley and Wang, 1993b), and human
topo IIα (Hammonds and Maxwell, 1997)
is enhanced after DNA binding. However,
topo II promotes one round of strand pas-
sage in the presence of a nonhydrolyzable
analog of ATP (Osheroff et al., 1983), sug-
gesting that ATP hydrolysis is dispensable
for catalysis per se. Steady-state kinetic
analyses under ATP-limiting conditions re-
vealed that two ATP molecules are hydro-
lyzed per DNA transport event. Studies
utilizing AMPPNP have indicated that ATP
hydrolysis, and release of products thereof,
is required for topo II turnover at the end
of the catalytic cycle (Osheroff et al., 1983).
 Recent studies using rapid quench tech-
niques and pre-steady-state analysis have
contradicted this view. These results sug-
gest that topo II hydrolyzes the two bound
ATP molecules sequentially (Harkins and
Lindsley, 1998; Harkins et al., 1998). The
first ATP is hydrolyzed very rapidly; this
hydrolysis occurs prior to DNA transport
and accelerates strand passage (Baird et al.,
1999). Hydrolysis of the second ATP mol-
ecule is linked to the opening of the top
“clamp” and enzyme turnover. The signifi-
cance of these findings in the context of the
topo II reaction cycle remains to be eluci-
dated.
D. Strand Passage
Two alternate models have been proposed
for the passage of the T segment through the
topo II-G segment complex. The “one-gate”
model posits that the T segment enters the
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7dimer through one gate (formed by the
N-terminal ATPase domains of the mono-
mers), traverses the double-strand break in
the G segment, and exits through the same
gate. This model requires the release, or a
major conformational change, of the G seg-
ment prior to T segment release. The “two-
gate” model hypothesizes that the T segment
enters and exits the topo II dimer using gates
located at opposite ends, leaving the topo II-
G segment association unchanged (Figure
1). Data from experiments using various
forms of catenated DNA substrates and
nonhydrolyzable analogs of ATP (Roca and
Wang, 1992; Roca and Wang, 1994), or an
intradimerically crosslinked topo II (Roca et
al., 1996) favor the two-gate model. In con-
trast, Lindsley (1996) demonstrated that a
topo II dimer consisting of two covalently
crosslinked monomers was capable of ca-
talysis. However, it is possible that the cova-
lent linkage at the end of the C-terminal do-
main may allow enough space for the DNA
to rearrange itself for another cycle of strand
passage. Taken together, the results discussed
above indicate that the two-gate model accu-
rately defines the mechanism of topo II-me-
diated strand passage.
E. Insights into Topo II Reaction
Mechanism Through Structural
Biology
The overall structural organization of
yeast topo II shows striking similarities to
the E. coli GyrA and GyrB, suggesting that
these subunits may have been joined to form
eukaryotic topo II. Alignment of yeast topo
II amino acid sequence with those of GyrA
(harboring the breakage/rejoining core) and
GyrB (harboring the ATPase domain) sub-
units reveals a high degree of sequence
homology (Lynn et al., 1986; Uemura et al.,
1986; Wyckoff et al., 1989). It has been
shown that the N-terminal portion of human
topo II is sufficient for the display of DNA-
dependent ATPase activity (Gardiner et al.,
1998). The C-terminal half of eukayotic topo
II harboring both the active site tyrosine and
dimerization domain is related to the GyrA
subunit, while the N-terminal half is ho-
mologous to the GyrB subunit. In addition,
eukaryotic type II topoisomerases have a
species-specific C-terminal tail consisting
of about 250 amino acids beyond the dimer-
ization domain (Uemura et al., 1986; Lynn
et al., 1986; Wyckoff et al., 1989). There
are a number of functions, both in vitro and
in vivo, attributed to the C-terminal domain.
These include nuclear localization (Shiozaki
and Yanagida, 1992; Jensen et al., 1996;
Mirski et al., 1997), multimerization
(Vassetzky et al., 1994), protein-protein in-
teraction (Kroll, 1997), modulation of DNA
binding (Crenshaw and Hsieh, 1993) and
regulation of catalytic activity (Cardenas
and Gasser, 1992; Cardenas et al., 1993). In
addition, genetic studies implicate a role for
this domain in maintaining topo II function
in vivo (Thomas et al., 1991; Caron et al.,
1994; Yoon et al., 1996). However, it must
be noted that certain portions of the C-ter-
minal domain are dispensable for catalytic
activity in vitro (Shiozaki and Yanagida,
1991; Crenshaw and Hsieh, 1993).
The molecular architecture of eukaryotic
topo II has emerged from a combination of
electron microscopy and X-ray crystallo-
graphic studies. Analysis of EM images of
both human and yeast topo II show a tripar-
tite structure. A large globular core compris-
ing the C-terminal part of the dimeric en-
zyme is connected by linkers to two smaller
N-terminal ATPase domains (Benedetti et
al., 1996; Schultz et al., 1997). The binding
of nonhydrolyzable ATP analogue resulted
in the formation of an internal tunnel for the
passage of a segment of DNA, as proposed
earlier using DNA binding and in vitro enzy-
matic assays (Schultz et al., 1997; Roca and
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8FIGURE 1. Cartoon depicting the two-gate model for topo II reaction mechanism. In the model, topo
II dimer, shown as two crescent-shaped monomers, binds to DNA designated as G segment (for
gated) and interacts with segment T (for transported) as a protein clamp in an “open” configuration.
Binding of two ATP molecules by topo II leads to the conformational change in the N-termini of
monomers, resulting in the trapping of the T segment.  Hydrolysis of one ATP precedes and
accelerates strand passage leading to the eviction of T segment through the lower gate. This
process generates topo II-G segment complex in a “closed” conformation. Subsequently, hydrolysis
of the second ATP molecule resets the upper clamp in an “open” conformation. Topo II-DNA
complex then is ready for the second cycle of catalysis (see text for further details).
Cr
iti
ca
l R
ev
ie
w
s i
n 
Bi
oc
he
m
ist
ry
 a
nd
 M
ol
ec
ul
ar
 B
io
lo
gy
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
12
2.
17
9.
87
.1
18
 o
n 
03
/0
2/
11
Fo
r p
er
so
na
l u
se
 o
nl
y.
9Wang, 1992; 1994). X-ray crystal structure
of the 92-kDa S. cerevisiae topo II spanning
amino acid residues 410 to 1202, which lacks
the ATP-binding domain but contains the
remaining portions of a functional enzyme,
has been determined (Berger et al., 1996).
An interesting feature of the three-dimen-
sional structure is that it shows topo II as a
dyadic enzyme composed of two crescent-
shaped monomers. Dimer contacts are estab-
lished at the tips of crescent near the C- and
N-termini of the fragment. These are the two
principal regions of contact in the dimer that
are stabilized by hydrophobic interactions at
the interface. This arrangement of contacts in
the dimer results in the formation of a central
cavity, which was predicted earlier by DNA
binding assays in the presence of AMPPNP
(Roca and Wang, 1992). As one might imag-
ine, the shape that the dimer adopts has been
likened to a “wasp’s” head (Wigley, 1996).
However, the structure that helped to under-
stand the organization of topo II by defining
the interactions between the monomers has
failed to provide a satisfactory explanation
regarding the positioning and cleavage of G
segment and the passage of T segment through
the central cavity. This issue was resolved in
the X-ray structure of 59-kDa fragment
of E. coli gyrase harboring the breakage-
reunion domain (Morais Cabral et al.,
1997). The gyrase structure reveals new
dimer contacts, a grooved surface for
binding the G segment, and a cluster of
conserved charged residues surrounding
the active site tyrosine. Based on the lo-
cation of the amino acid residues, this
structure suggests an enzymatic mecha-
nism of cleavage of G segment and a
pathway for the passage of the T seg-
ment through the second gate of the dy-
adic enzyme. However, the biochemical
or structural details of how the passage
of T segment is achieved through the
gate are still poorly understood.
 Some of the potential biological impli-
cations of conserved and nonconserved re-
gions in topo II have been most clearly
revealed in S. cerevisiae. Site-directed mu-
tagenesis of functionally important regions
has indicated that the catalytic activity of
human and S. cerevisiae topo II is tolerant
to modifications at the inter-domain spac-
ing. Collectively, it appears that the con-
served domains are essential for sustained
mitotic growth of S. cerevisiae and for en-
zymatic activity in vitro (Jensen et al., 1996).
A recent study has implicated that in human
topo II, the region between ATPase and
cleavage/religation domain is essential for
effective inter-domain communication con-
sequent to ATP binding (Bjergbaek et al.,
2000).
F. Inhibition of Topo II Action
 Topo II plays a vital role in maintain-
ing cell viability; consequently, it is an
important target for antiproliferative inter-
vention. The cellular target for a large num-
ber of antitumor drugs is topo II. These
include DNA intercalating agents such as
ellipticine (Chu and Hsu, 1992) and
amiloride (Besterman et al., 1987), and
nonintercalators such as etoposide and
teniposide (Chen et al., 1984). Both of these
function directly by interfering with the
cleavage/religation step of the catalytic
cycle, by either enhancing the cleavage
reaction (e.g., ellipticine; Froelich-Ammon
et al., 1995a), or inhibiting religation (e.g.,
etoposide; Robinson and Osheroff, 1991;
Burden et al., 1996). This results in stabi-
lization of the “cleavable complex”, thereby
leading to the accumulation of potentially
lethal double-strand breaks. Although the
cleavage step is the main target of these
drugs, they also inhibit other aspects of the
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catalytic cycle such as ATP hydrolysis
(Robinson et al., 1993) and strand passage
(Chen et al., 1984). Certain classes of drugs
inhibit topo II activity by interfering with
the catalytic cycle at steps other than DNA
cleavage/religation equilibrium. For ex-
ample, aclarubicin inhibits noncovalent
DNA binding (Sørensen et al., 1992), bis-
dioxopiperazines lock the enzyme in the
“closed clamp” form (Roca et al., 1994),
while staurosporine inhibits the transfer of
phosphodiester bonds from DNA to the
active site tyrosine (Lassota et al., 1996).
Antitumor agents exert their effects via
the formation of a topo II-DNA-drug ternary
complex, wherein the drug may interact with
both the enzyme and the DNA (Froelich-
Ammon et al., 1995a). Accordingly, the effi-
cacy of these agents is assessed by a variety
of assays and phenotypes. Investigations have
shown that resistance to these drugs arise
from changes in the cellular levels of topo II
(Pommier et al., 1986; Ganapathi et al., 1993)
or alteration of its subcellular localization
(Boege et al., 1993). Additional evidence
indicates that nucleotide sequence and incor-
poration of substrate DNA into nucleosomes
differentially affect the extent of inhibition
by topo II-directed drugs (Sørensen et al.,
1990; Spitzner et al., 1995; Galande and
Muniyappa, 1997; Larsen and Skladanowski,
1998). There is good evidence that cells that
have become resistant to antitumor drugs
accumulate point mutations (Froelich-
Ammon et al., 1995b; Hsiung et al., 1995)
and deletions (Campain et al., 1994) in the
coding portion of topo II gene. In addition,
altered phosphorylation of topo II has also
been noted in the resistant cells (DeVore et
al., 1992; Ritke et al., 1994).
 Various endogenous DNA lesions are
also capable of poisoning topo II activity.
UV-radiation-induced cyclobutane pyrimi-
dine dimers inhibit topo II activity by inter-
fering with strand passage (Corbett et al.,
1991). The presence of abasic sites in the
DNA affects the cleavage step of the
topoisomerization reaction. When these sites
are located within the four-base overhang
generated by DNA incision, they enhance
the rate of topo II-mediated scission (Kingma
et al., 1995). Apurinic sites are more potent
than apyrimidinic sites, and enhance cleav-
age by 10- to 20-fold (Kingma and Osheroff,
1997a). Interestingly, abasic sites just out-
side the site of cleavage inhibit strand scis-
sion (Kingma et al., 1995). Base mismatches
(Bigioni et al., 1996) and cytosine deamina-
tion (Kingma and Osheroff, 1997b) also af-
fect DNA strand scission, and do so with a
position specificity identical to that observed
for abasic sites. Cytosine methylation has a
negative effect on topo II-mediated cleavage
and may affect the site-specificity of antitu-
mor drugs (Leteurtre et al., 1994). It is be-
lieved that all these endogenous lesions af-
fect topo II activity by inducing structural
perturbations in the DNA (reviewed in
Kingma and Osheroff, 1998).
Although anti-topo II agents have been
valuable in gaining insights into the mecha-
nistic aspects of topo II, the basis of drug-
induced cell death is not well understood.
Accumulation of “cleavable complexes”
leads to inhibition of replication (Del Bino
et al., 1991), enhancement of sister chroma-
tid-exchange (Pommier et al., 1985), chro-
mosomal translocation (Charron and
Hancock, 1991), and arrest of p34cdc2 kinase
induction (Roberge et al., 1990). While the
ultimate result of these events is apoptotic
cell death, the molecular links in the signal-
ing pathway are obscure (reviewed in
Kaufman, 1998).
IV. CELLULAR FUNCTIONS OF
TOPOISOMERASE II
Due to its ability to promote topological
interconversions of DNA, topo II plays a
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vital role in multiple cellular processes such
as chromosome segregation, chromosome
condensation, transcription, replication,
maintenance of chromosome structure, re-
combination, and maintenance of genomic
integrity. The role(s) of topo II in these
processes is reviewed below.
A. Mitotic and Meiotic
Chromosome Segregation
Sundin and Varshavsky (1981) first re-
ported that topo II is essential for proper
segregation of chromosomes. Their studies
on SV40 demonstrated the accumulation of
catenated dimers after the arrest of segrega-
tion of newly replicated genomes. Similar
results were obtained using topo II-directed
inhibitors in intact cells (Yang et al., 1987;
Snapka et al., 1988). Cytogenetic studies
provided firm evidence for the involvement
of topo II in chromosome segregation in
Schizosaccharomyces pombe and Saccha-
romyces cerevisiae. S. pombe cells bearing
a top2ts mutation displayed aberrant mitosis
when grown at a nonpermissive tempera-
ture (Uemura and Yanagida, 1986; Uemura
et al., 1987), leading to chromosome break-
age and cell death. Similarly, growth of
S. cerevisiae top2ts cells at a nonpermissive
temperature led to lethality when the cells
were allowed to progress through mitosis
(Holm et al., 1985). In addition, replication
of 2 µ plasmid in top2ts cells at nonpermis-
sive temperature led to the accumulation of
multiply intertwined catenated dimers, indi-
cating that topo II activity was required for
segregation of circular DNA molecules
(DiNardo et al., 1984). Cytological studies
showed a higher frequency of chromosome
nondisjunction, at nonpermissive tempera-
tures, in top2ts cells, suggesting that aneup-
loidy may be responsible for lethality (Holm
et al., 1989). Subsequently, Spell and Holm
(1994) detected chromosome fragmentation
in S. cerevisiae top2ts cells after cell divi-
sion at a nonpermissive temperature. Stud-
ies in various mammalian cell lines (Downes
et al., 1991; Charron and Hancock, 1991;
Ishida et al., 1994) and Xenopus laevis oo-
cyte extracts (Shamu and Murray, 1992)
revealed that topo II inhibitors blocked chro-
mosome segregation at the metaphase/
anaphase transition. Injection of teniposide
or anti-topo II antibodies into Drosophila
embryos (Buchenau et al., 1993) yielded
similar results in vivo. Consistent with the
above findings, Downes et al. (1994) iden-
tified a catenation-sensitive G2 checkpoint
in mammalian cells.
 Cytogenetic studies on top2 mutant
strains of S. cerevisiae revealed that topo II
activity was also required for segregation of
recombined homologs during meiosis (Rose
et al., 1990; Spell and Holm, 1994).
S. cerevisiae top2cs mutants failed to finish
the first meiotic division when grown at
nonpermissive temperature. This defect was
overcome by the presence of a mutation that
impaired recombination, confirming that
topo II activity was necessary for resolving
recombined chromosomes (Rose et al.,
1990). Cytological analysis of S. cerevisiae
top2 strains identified an important cell cycle
checkpoint at late pachytene stage prior to
the formation of the meiotic spindle (Spell
and Holm, 1994). Together these results
suggest that topo II activity is essential for
resolving inter- and intrachromosomal
tangles generated during meiotic recombi-
nation.
B. Transcription and DNA
Replication
There is considerable evidence to sug-
gest that unwinding of duplex DNA and
helix tracking during transcription, DNA
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replication, and recombination results in
marked changes in DNA supercoiling. Con-
sequently, topoisomerase activity might be
required to annul these changes and allow
successful completion of ongoing processes
(Liu and Wang, 1987; Dröge, 1994, and
references therein). Consistent with this no-
tion, genetic studies using top1 top2 strains
of S. cerevisiae have demonstrated the re-
quirement for topo II as a “swivelase” dur-
ing transcription and DNA replication (Brill
et al., 1987; Brill and Sternglanz, 1988;
Kim and Wang, 1989a; Ishimi et al., 1992).
Several studies using in vitro-reconstituted
systems, immunodepletion, or use of spe-
cific inhibitors also suggested the require-
ment of topo II in the initiation (Halmer et
al., 1998) and late elongation phase of SV40
minichromosome replication (Yang et al.,
1987; Snapka et al., 1988; Ishimi et al.,
1992). However, it must be noted that
topoisomerase I could substitute for the
“swivelase” function of topo II in all of the
cases mentioned above.
C. Maintenance of Chromosome
Structure
 A number of observations indicate that
topo II is an abundant chromosomal protein
in eukaryotes. One possible explanation for
the differences in the abundance of topo II
family of proteins between prokaryotes and
eukaryotes might have to do with the linear
structure and complex organization of eu-
karyotic chromosomes. Accordingly, sub-
stantial experimental evidence indicates that
topo II plays a key role in chromosomal
scaffolding. Biochemical characterization of
SC1, an abundant, nonhistone chromosomal
protein, revealed that it is identical to topo
II (Earnshaw et al., 1985; Gasser et al.,
1986). Immunolocalization methods showed
that topo II localizes along the central axial
region that traversed the length of each chro-
matid, including the kinetochore (Earnshaw
and Heck, 1985; Gasser et al., 1986;
Taagepaara et al., 1993). A similar pattern
of distribution was also seen in meiotic chro-
mosomes of rooster (Moens and Earnshaw,
1989) and yeast (Klein et al., 1992). The
presence of topo II was shown to be essen-
tial for the formation of a proper kineto-
chore structure in a variety of species
(Rattner et al., 1996). The preferential bind-
ing of topo II to AT-rich scaffold-associ-
ated regions (SARs) in vitro (Adachi et al.,
1989), and the positioning of long range
topo II cleavage sites in vivo (Gromova et
al., 1995), led to the suggestion that topo II
may be localized at the base of chromo-
somal domains. Together these results ar-
gue that topo II plays a vital role in the
maintenance of mitotic (and meiotic) chro-
mosome structure. However, studies in Xe-
nopus (Hirano and Mitchison, 1993) and
Drosophila (Whalen et al., 1991; Swedlow
et al., 1993) indicated that topo II was local-
ized uniformly all along the chromosome
and that its continuous association was not
necessary for the maintenance of chromo-
some structure. These discrepancies might
arise due to the method of sample prepara-
tion and fixation, inherent species-specific
differences in the chromosomal localization
of topo II, and different epitope-specifici-
ties of the anti-topo II antibodies used. Also,
the distribution of topo II in any given or-
ganism may itself change as cells progress
through the cell cycle (reviewed by
Warburton and Earnshaw, 1997).
D. Chromosome Condensation
 In contrast to the situation discussed
above, an essential role for topo II in chro-
mosome condensation has been demon-
strated unambiguously in a variety of
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model organisms. Genetic analysis in the
budding and fission yeasts showed that
topo II is necessary for chromosome con-
densation (Holm et al., 1985; Uemura et
al., 1987). Biochemical studies using topo
II inhibitors and cell-free extracts from
Xenopus (Newport, 1987; Newport and
Spann, 1987; Adachi et al., 1991; Hirano
and Mitchison, 1993), chicken and mam-
mals (Wood and Earnshaw, 1990) are
consistent with the above notion. These
results were confirmed using entire Droso-
phila embryos (Buchenau et al., 1993)
and mammalian cells (Roberge et al.,
1990; Ishida et al., 1994; Downes et al.,
1994; Bojanowski et al., 1998). Interest-
ingly, recent studies using catalytically
inactive topo II (Bojanowski et al., 1998;
Mo and Beck, 1999) demonstrated that
the enzymatic activity of topo II was not
required for chromosome condensation.
These results suggest that the formation
of higher order chromatin structure may
be mediated solely through DNA-binding
interactions of topo II. There is consider-
able evidence to suggest that topo IIα is
the primary mediator of chromosome con-
densation (Taagepaara et al., 1993; Kimura
et al., 1996b; Meyer et al., 1997; Grue et
al., 1998).
E. Recombination and Genomic
Integrity
Topo II (together with topo I) is in-
volved in suppressing mitotic recombina-
tion in the rDNA cluster of S. cerevisiae
(Christman et al., 1988). In this regard, Kim
and Wang (1989b) demonstrated that in a
top1 top2-4 mutant, one-half of total rDNA
existed as extrachromosomal rings. Expres-
sion of either TOP1 or TOP2 led to integra-
tion of these rings into the chromosome. It
has been suggested that the movement of
transcription machinery across repetitive
DNA sequences creates a topological situa-
tion favoring recombination and the subse-
quent excision of these sequences.
Topoisomerases are required to suppress this
phenomenon and maintain genomic integ-
rity.
The isolation and characterization of a
type II DNA topoisomerase from the
archaebacterium Sulfolobus shibatae (Bergerat
et al., 1997) led to interesting insights into the
involvement of topoisomerase-like proteins in
meiotic recombination. This enzyme bears ho-
mology to S. cerevisiae Spo11, which is in-
volved in meiotic recombination. Mutagen-
esis studies revealed that Spo11p utilizes a
tyrosine residue to inflict a double-strand break
in DNA, analogous to the mechanism used by
type II DNA topoisomerases (Bergerat et al.,
1997). It is speculated that Spo11 is a diver-
gent form of topo II that has lost the ability to
reseal the double-strand break (Wang, 1997;
Haber, 1997). Nonetheless, these observations
imply that topoisomerase II-like components
might play an important role in meiotic re-
combination.
The mechanism of topoisomerization
reaction promoted by topo II involves the
formation of a covalent protein–DNA inter-
mediate. This raises the possibility that the
enzyme might mediate illegitimate recom-
bination through subunit exchange. This
premise is based on the observation that
E. coli DNA gyrase (Ikeda et al., 1982) and
phage T4 topoisomerase II (Ikeda, 1986a,
1986b) catalyzed illegitimate recombination
in vitro. Subsequent studies demonstrated
that eukaryotic enzymes such as calf thy-
mus DNA topo II (Bae et al., 1988) and
Drosophila topo II (Gale and Osheroff, 1990,
1992) also mediate the formation of hetero-
duplex DNA in vitro. In this regard,
Lamhasni et al. (1995) reported that the
yeast topo II dimer had a dissociation con-
stant (Kd) of the order of 106 M-1, implying
that the intermonomer interaction is rela-
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tively weak. On the other hand, Tennyson
and Lindsley (1997) demonstrated that the
yeast enzyme existed as a stable dimer with
a dissociation constant (Kd) of the order of
1011 M-1. It was also shown that dissociation
of human topo IIα and topo IIβ dimers was
undetectable in vitro and in vivo (Biersack
et al., 1996; Gromova et al., 1998).
In mammalian cells, topo II-mediated
rearrangements are observed in cells that
are treated with anti-topo II drugs (reviewed
in Felix, 1998). While crossovers at topo II
cleavage sites led to the formation of hybrid
DNA in vivo (Zhou et al., 1997), an over-
whelming majority of recombinants dem-
onstrated processing of DNA prior to hy-
brid formation. These results suggest that
topo II-mediated illegitimate recombination
in vivo may be a consequence of the physi-
cal disruption of the trapped DNA- topo II
complex, rather than subunit exchange.
V. REGULATION OF TOPO II
EXPRESSION
A. Transcriptional and Post-
transcriptional Regulation of
topo II
1. Promoter Structure
Topo IIα gene promoters from human,
mouse, hamster, and rat have been isolated
and characterized. The human promoter
sequence is devoid of a TATA-box, but is
GC rich, with a number of putative regula-
tory motifs embedded in the first 650 base
pairs upstream of the translation initiation
site (Hochhauser et al., 1992). These mo-
tifs include a consensus half-site for the
binding of Myc/Max factors, two Sp1 ele-
ments, and a proximal Myb-binding site.
The Myb site regulates topo IIα expression
in human leukemic cells and HeLa cells
(Brandt et al., 1997). The functional rel-
evance of the remaining motifs is unclear.
In addition, the topo IIα promoter also
contains five inverted CCAAT boxes
(ICBs), a cell cycle-dependent element
(CDE) between ICB2 and ICB3, and an
ATF-binding site between ICB3 and ICB4.
The region up to 617 base pairs upstream
of the translation initiation site contains all
of the above-mentioned motifs and directs
maximal expression of a linked reporter
gene in HeLa cells (Hochhauser et al.,
1992). Molecular analysis has revealed that
ICB1 governs repression of topo IIα tran-
scription during G0/G1 stage (Falck et al.,
1999); activation of topo IIα expression
following heat-shock (Furakawa et al.,
1998) involves alleviation of ICB1-medi-
ated repression. ICB2 is involved in the
repression of topo IIα transcription fol-
lowing confluence-mediated arrest of cell
division (Isaacs et al., 1996). Interestingly,
p53 down-regulates human topo IIa tran-
scription from the minimal (100 bp) pro-
moter. The mechanism by which it does so
is unclear (Sandri et al., 1996; Wang et al.,
1997).
The hamster topo IIα promoter displays
a very high degree of homology to its hu-
man homologue, but there is evidence to
suggest that the ICBs may be functionally
different (Ng et al., 1995). Similarly, the
mouse topo IIα promoter shows a high de-
gree of homology to the human and hamster
promoters except that it contains two addi-
tional CCAAT boxes in the sense orienta-
tion (Adachi et al., 1997).
 Molecular analysis of the rat topo IIα
promoter has revealed significant similarity
with the human topo IIα promoter. The first
250-bp sequence upstream of the transla-
tion initiation site of rat topo IIα bears a
70% identity with the corresponding human
sequence. Although the sequence further up-
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stream shows less similarity, the spatial or-
ganization of the cis-acting elements is pre-
served. The rat topo IIα promoter also con-
tains an AP1-binding site that is not found
in the human, hamster, or mouse promoters.
In addition, DNase I footprinting analysis
with HeLa cell nuclear extracts has pro-
vided evidence for regulation of the rat topo
IIα promoter by binding of factors to the
Sp1 motifs (Park et al., 1995). Mutational
analysis has revealed that ICB4 is required
for basal transcription, while Sp1 controls
up-regulation during cell-proliferation (Yoon
et al., 1999).
 The regulation and promoter structure
of topo IIβ has not been studied extensively.
The 5' flanking region of human topo IIβ
gene has been characterized. Although the
promoter is devoid of a TATA box and con-
tains GC-rich sequence, it has no obvious
homology to the topo IIa promoter. Interest-
ingly, sequences within the first intron, which
interact with AP2 and Sp1 proteins, contrib-
ute to promoter activity (Ng et al., 1997).
2. Cell Cycle Stage-Specific
Regulation
Analysis of whole tissues of rat have
shown that expression of topo IIα specific-
mRNA is highest in proliferating tissues,
while topo IIβ mRNA levels do not corre-
late with proliferation state (Tsutsui et al.,
1993). In HeLa cells, topo IIα mRNA levels
rise 10-fold in late S-phase compared with
the levels in G1-phase and then decline rap-
idly following mitosis. In contrast, topo IIβ
mRNA levels show a twofold increase dur-
ing progression through the cell cycle (Isaacs
et al., 1998). Run-on transcription assays
indicated a twofold difference in the rate of
transcription initiation of topo IIa during
cell cycle progression in HeLa cells
(Goswami et al., 1996). These results sug-
gest that control of mRNA expression might
be occurring at the level of mRNA stability.
This is supported by the studies of Goswami
et al. (1996), who showed that the half-life
of topo IIα mRNA was 4 h during S-phase
but 30 min in G1 phase. The 3′ UTR was
found to be necessary and sufficient for cell
cycle stage-specific control of topo IIα
mRNA levels (Goswami et al., 2000). This
control was mediated via the interaction of
redox-sensitive protein complexes with the
UTR (Goswami et al., 2000; see Figure 2).
In contrast, studies on mouse topo IIα gene
expression demonstrated that the mRNA sta-
bility was not governed by the 3′ UTR se-
quence (Kobayashi et al., 1998).
B. Posttranslational Regulation
1. Regulation of Topo II Activity
by ADP-Ribosylation
ADP-ribosylation of proteins by poly
(ADP)-ribose polymerase plays an important
role in the regulation of many cellular pro-
cesses. Topo II undergoes ADP-ribosylation
in vitro with concomitant decrease in catalytic
activity (Darby et al., 1985). Scovassi et al.
(1993) have demonstrated that HeLa cell topo
IIα is ADP ribosylated in intact cells. How-
ever, the treatment of cells with mutagens
failed to enhance ADP ribosylation of topo II.
The physiological significance of these results
is unclear.
2. Regulation of Topo II by
Phosphorylation
 Regulation of protein function by phos-
phorylation-dephosphorylation is a mecha-
nism widely used in biological systems to
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modulate metabolic pathways (Hunter,
1987). In vivo, topo II exists as a phosphop-
rotein, including yeasts (Cardenas et al.,
1992; Shiozaki and Yanagida, 1992), Droso-
phila (Sander et al., 1984; Ackerman et al.,
1988), mouse (Saijo et al., 1990), human
(Heck et al., 1989; Kroll and Rowe, 1991),
and the sponge Geodia cydonium (Rottmann
et al., 1987).
a. Kinases Involved in Topo II
Phosphorylation
 Casein kinase II (CKII) has been iden-
tified as the primary candidate involved in
the phosphorylation of topo II in vivo. The
role of CKII in the phosphorylation of topo
II has been substantiated in S. cerevisiae
(Cardenas et al., 1992) and Drosophila
(Ackerman et al., 1985, 1988). In the bud-
ding yeast, CKII copurifies with topo II
and reactivates the dephosphorylated, in-
active form of the enzyme in vitro
(Cardenas et al., 1993). In addition, immu-
noprecipitation with anti-topo II or anti-
CKII antibodies showed that topo II exists
as a complex with CKII in vivo, and both
the components of this complex are cata-
lytically active (Bojanowski et al., 1993).
Protein kinase C (PKC) also phosphory-
lates topo II of S. pombe (Shiozaki and
Yanagida, 1992), G. cydonium (Rottmann
et al., 1987), and humans (Wells et al.,
1995) in vivo. In addition to CKII and PKC,
kinases such as Ca2+/calmodulin-dependent
protein kinase, p34cdc2 kinase and several
MAP kinases phosphorylate topo II in vari-
ous systems (Cardenas et al., 1992; Wells
and Hickson, 1995). Mammalian extracel-
lular-signal-regulated kinases, ERK1 and
ERK2, have also been shown to phospho-
rylate topo IIα in vitro and in vivo (Shapiro
et al., 1999).
b. Phosphorylation Sites on Topo II
 In all organisms studied so far, topo II
is phosphorylated primarily on serine and
threonine residues in its species-specific
C-terminal domain. In S. cerevisiae and
Drosophila, both CKII and PKC phospho-
rylate topo II at closely juxtaposed sites
(Cardenas et al., 1992, 1993; Corbett et al.,
1992b, 1993). The modification of human
topo IIα by proline-directed MAP kinases
also occurs in the C-terminal domain (Wells
and Hickson, 1995). While some residues
remain phosphorylated at all times, the sta-
tus of other sites varies depending on the
stage of the cell cycle (discussed below). A
notable exception to the above generaliza-
tion is the PKC-mediated phosphorylation
of S. pombe topo II (Shiozaki and Yanagida,
1992) and human topo IIα (Wells et al.,
1995). In both these cases, the modified
serine residue resides in the N-terminal do-
main.
c. Cell Cycle Stage-Specific
Regulation of Phosphorylation
 Topo II phosphorylation varies as a
function of the phase of the cell cycle with
maximal modification detectable in the M
phase. A detailed characterization of this
phenomenon has been performed with
S. cerevisiae and human topo II. Phospho-
rylation of S. cerevisiae topo II is maximal
during mitosis with the increase being
mainly quantitative, that is, more number of
molecules are phosphorylated at the same
sites (Cardenas et al., 1992). Few minor
mitosis-specific sites, which appear to be
targets of p34cdc2 kinase are present, but
have not yet been characterized. In humans,
the situation differs due to the presence of
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two isoforms of topo II: topo IIα and topo
IIβ. Phosphorylation of topo IIα is both
qualitatively and quantitatively different
during various stages of the cell cycle (Wells
et al., 1995; Wells and Hickson, 1995). For
example, threonine-1342, serine-1376, and
serine-1524 are phosphorylated to similar
extents in mitotic as well as in interphase
cells (Wells et al., 1994; Ishida et al., 1996),
while serine-1212, -1246, -1353, -1360, and
-1392 are modified only in M phase (Wells
and Hickson, 1995). The latter group of
residues is believed to be the target of pro-
line-directed MAP kinases. Interestingly,
PKC-mediated phosphorylation of serine-
29 is also mitosis specific (Wells et al.,
1995). Topo IIβ is phosphorylated in vivo
(Kimura et al., 1994a, 1994b) and interacts
with the mitotic phosphoprotein antibody
MPM-2 (Taagepera et al., 1993). Mitosis-
specific phosphorylation of topo IIβ leads
to an increase in its apparent molecular
weight as detected by denaturing gel elec-
trophoresis (Kimura et al., 1994a, 1994b).
d. Effect of Phosphorylation on the
Functional Activity of Topo II
The effect of phosphorylation on topo II
catalytic activity appears to be species spe-
cific. Dephosphorylation of S. cerevisiae
topo II leads to the complete loss of cata-
lytic activity. However, a C-terminal trun-
cated form of the enzyme that lacks all of
the phosphorylation sites is fully active
(Cardenas et al., 1993). This observation
has given rise to the speculation that the
C-terminal domain may be playing a nega-
tive regulatory role and phosphorylation is
required to alleviate this inhibition (Cardenas
and Gasser, 1993). Phosphorylation also
promotes multimerization of S. cerevisiae
topo II (Vassetzky et al., 1994) and modu-
lates its interactions with DNA (Dang et al.,
1994). In contrast to budding yeast topo II,
phosphorylation apparently does not play
any discernible role in regulating the cata-
lytic activity of S. pombe topo II (Shiozaki
and Yanagida, 1992).
 The mechanism by which phosphory-
lation enhances catalytic activity has been
elucidated in detail using Drosophila topo
II. Modification leads to an increase in the
rate of ATP hydrolysis, which causes an
increase in enzyme turnover (Corbett et al.,
1992b, 1993). The situation in higher eu-
karyotes is somewhat complex, partly due
to the existence of two isoforms of topo II.
Phosphorylation of mouse topo IIα led to
significant increase in catalytic activity
(Saijo et al., 1990). A four- to sevenfold
increase in catalytic activity of topo IIα was
also observed after phosphorylation by
ERK1 and ERK2 (Shapiro et al., 1999).
However, others have found that phospho-
rylation has no role in this process, and that
the increase observed could be attributed to
the high concentrations of glycerol and topo
IIα used in these assays (Kimura et al.,
1996a). It has been shown that phosphory-
lation differentially affects the binding of
human topo IIα and topo IIβ to the mitotic
chromosome (Kimura et al., 1996b). These
results suggest that phosphorylation may
modulate topo II catalytic activity by influ-
encing the interaction of topo II with DNA.
Taken together these observations indicate
that the effects of phosphorylation on topo
II are species specific and exert their influ-
ence at multiple stages of the reaction cycle.
3. Regulation of Topo II by
Protein-Protein Interactions
 A significant body of evidence suggests
that topo II activity may be regulated by ho-
mologous and heterologous protein-protein
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interactions in vivo. S. cerevisiae topo II is
associated with casein kinase II in vivo. Phos-
phorylation of S. cerevisiae topo II by casein
kinase II is required for activity and also regu-
lates its oligomeric status. Multimerization of
topo II is believed to play a vital role in its
ability to participate in chromatin condensa-
tion. Topo II physically interacts with Sgs1p
(Watt et al., 1995), a homolog of RecQ helicase
in a functionally relevant form. Sgs1 mutants
are defective in chromosome segregation and
show increased levels of recombination (Watt
et al., 1995). Topo II also interacts with Pat1p
via its C-terminal domain (Wang et al., 1996).
pat1 mutants display phenotypes similar to
those of top2ts mutants at restrictive tempera-
tures. Drosophila topo II interacts with the
barren gene product, and apparently the inter-
action is necessary for proper chromosome
segregation (Bhat et al., 1996). Human topo
IIα heterodimerizes with topo IIβ in vivo
(Biersack et al., 1996). αβ heterodimers are
biochemically distinct from both αα and ββ
homodimers; however, their physiological role
is unclear (Gromova et al., 1998). Human
topo IIα also associates with CREB, ATF2,
and c-Jun. This interaction affects the cata-
lytic activity of topo II by increasing the rate
of DNA religation (Kroll et al., 1993). In con-
trast, the association of human topo IIα with
14-3-3ε (Kurz et al., 2000) and retinoblastoma
protein (Bhat et al., 1999) negatively modu-
lates topo II activity. Interaction of human
topo IIα with casein kinase II stabilizes topo
II activity in a phosphorylation-independent
manner (Redwood et al., 1998). Mammalian
topo IIα also associates with ERK1 and ERK2
in vivo (Shapiro et al., 1999). The association
with the diphosphorylated form of ERK1, in
the absence of topo IIα phosphorylation, leads
to an increase in topo II catalytic activity.
Human topo IIα interacts with CAD nuclease,
in an association that enhances its decatenation
activity in vitro and plays a role in apoptotic
execution (Durrieu et al., 2000). Recently, it
has been demonstrated that both the isoforms
of human topo II interact with p53 (Cowell et
al., 2000). p53 stimulates the catalytic activity
of human topo IIα by enhancing the rate of
ATP hydrolysis (Kwon et al., 2000). This
phenomenon is intriguing in light of the ob-
servation that p53 downregulates transcrip-
tion from the topo IIα promoter (Sandri et al.,
1996; Wang et al., 1997). Topo IIβ has been
shown to interact with CD3ε. The signifi-
cance of this association is obscure (Nakano
et al., 1996). It is evident that topo II interacts
with a plethora of proteins in vivo. It is pos-
sible that these interactions may be crucial in
the regulation of topo II function, in response
to various signaling molecules, in different
cell types.
VI. SUMMARY AND PROSPECTS
Topo II is an essential nuclear enzyme
that plays key role(s) in DNA metabolism
and chromosome organization. Its major
function is to regulate the topological state
of DNA during replication, recombination,
and chromosome condensation and segre-
gation. A combination of genetic, biochemi-
cal, molecular biological, and computer
analyses of the structural and evolutionary
relationships have helped establish the uni-
versality of topo II in eukaryotes. From the
foregoing discussion, it is clear that recent
years have witnessed tremendous progress
in our understanding of the molecular ba-
sis by which topo II is regulated in eukary-
otic cells. Several new mechanisms,
including structural and enzyme modifica-
tions of DNA and acidic pH environment,
have been shown to stimulate topo II-me-
diated DNA cleavage, suggesting that topo
II is highly vulnerable to chemical and
physical assaults. Of particular importance
is the observation that topo II is involved
in both cell proliferation and apoptosis (Li
et al., 1999; Durrieu et al., 2000). The de-
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tails of how topo II activity is coordinated
between these two dissimilar cellular pro-
cesses remain to be defined. X-ray crystal
structure of the 92-kDa S. cerevisiae topo
II has revealed interactions between differ-
ent domains and has provided insights into
topo II reaction mechanism. However, the
crystal structures of topo II holoenzyme, a
complex of holoenzyme with its substrate
DNA and the “cleavable complex”, remain
to be determined. In yeast, topo II appears
to be essential for chromosome segrega-
tion in both vegetatively dividing and mei-
otic cells. The role of topo II in chromo-
some segregation in vertebrate cells remains
obscure: this function could be established
by using null or dominant-negative mu-
tants of mouse topo II. On the biomedical
front, many antitumor drugs are known to
poison topo II, resulting in cell death. These
findings further emphasize the importance
of developing potent topo II-based phar-
maceuticals for cancer treatment. Thus,
chemists and pharmacologists have much
more incitement to develop potent com-
pounds that would interfere with the cata-
lytic cycle of topo II. There is persuasive
evidence that topo IIα is intrinsically the
major isoform in proliferating mammalian
cells; therefore, one can develop com-
pounds that interact preferentially with dif-
ferent isoforms of topo II. In yeast, SGS1
(E. coli RecQ homologue believed to be
involved in aging) interacts with topo II
(Watt et al., 1995; Sinclair and Guarente,
1997). The exact physiological relevance
of the interaction between Sgs1p and
topoisomerases in humans is not yet clear.
Considering the growing interest of struc-
tural biologists, cancer researchers, and in-
vestigators focusing on various aspects of
DNA metabolism, a clearer vision of spe-
cific and specialized functions of topo II
awaits us in the near future.
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